Emerging Company Profile
PepGen: $112.5M round for cell-penetrating oligos and a Boston build-out
Emerging Company Profile: PepGen’s crossover round to take at least two muscular dystrophy assets into the clinic
PepGen’s crossover round will help the company to take at least two muscular dystrophy programs into the clinic and build out its new headquarters in Boston.
Aug 6, 2021 | 12:53 AM GMT
With a fresh $112.5 million in crossover funding, PepGen is prepared to take at least two muscular dystrophy therapies into